Drug · CHEMBL476
DACARBAZINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DACARBAZINE. Drugs and targets, record CHEMBL476. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL476
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Biocarbazine r, DIC, DTIC, Dacarbasine, Dacarbazina, Dacarbazinum, Decarbazine, Dicarbazine, NCI C04717, NSC-45388
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 40 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases40
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 40Source Open Targets
See all 40 diseasesTrials203
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | Phase 3 | 1,334 | 2018-11-27 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | Phase 3 | 994 | 2025-06-12 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT00091572 | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) | Phase 3 | 859 | 2009-03-12 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT00003389 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | Phase 3 | 854 | 2015-09-03 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT00324155 | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma | Phase 3 | 681 | 2014-03-10 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT01006980 | A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | Phase 3 | 675 | 2011-11-16 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT01343277 | A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | Phase 3 | 579 | 2016-01-28 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT00864253 | A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | Phase 3 | 529 | 2014-06-05 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT00911443 | Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma | Phase 2 | 488 | 2009-06-02 | dacarbazine | Its name | ClinicalTrials.gov |
| NCT01327885 | Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma | Phase 3 | 452 | 2017-02-28 | dacarbazine | Its name | ClinicalTrials.gov |
1 to 10 of 203
See all 203 trialsComparisons in its trials63
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values | 662 of 662 | 658 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| A+AVD vs ABVD: deaths from any cause | 9 of 662 | 13 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| A+AVD vs ABVD: serious adverse events | 284 of 662 | 178 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Overall Survival | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Event-free Survival (EFS) | 52 of 487 | 91 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Progression Free Survival (PFS) | 41 of 487 | 81 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): deaths from any cause | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): serious adverse events | 140 of 481 | 18 of 476 | 957 | NCT03907488 | Trial comparisons |
| Temozolomide vs Dacarbazine: serious adverse events | 124 of 419 | 100 of 421 | 840 | NCT00091572 | Trial comparisons |
| Arm A (ABVD) vs Arm B (Stanford V): serious adverse events | 355 of 414 | 401 of 422 | 836 | NCT00003389 | Trial comparisons |
1 to 10 of 63
See all 63 comparisons in its trialsPapers from its trials190
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL476
GET https://conductscience.org/api/drugs/v1/CHEMBL476/diseases?page=2